These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 12542598

  • 1. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.
    J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
    [Abstract] [Full Text] [Related]

  • 2. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 3. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 4. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [Abstract] [Full Text] [Related]

  • 5. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [Abstract] [Full Text] [Related]

  • 6. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [Abstract] [Full Text] [Related]

  • 7. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K, REVERSE Investigators.
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
    [Abstract] [Full Text] [Related]

  • 8. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
    [Abstract] [Full Text] [Related]

  • 9. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
    Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Terlipressin Study Group.
    Gastroenterology; 2008 May; 134(5):1360-8. PubMed ID: 18471513
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.
    Eur J Med Res; 2004 Feb 27; 9(2):78-82. PubMed ID: 15090293
    [Abstract] [Full Text] [Related]

  • 11. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug 27; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 12. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
    Goyal O, Sidhu SS, Sehgal N, Puri S.
    J Assoc Physicians India; 2016 Sep 27; 64(9):30-35. PubMed ID: 27762512
    [Abstract] [Full Text] [Related]

  • 13. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan 27; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 14. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
    Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F.
    Hepatology; 2007 Dec 27; 46(6):1863-71. PubMed ID: 18027874
    [Abstract] [Full Text] [Related]

  • 15. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr 27; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV, Mittal S, Kasturi KS, Sood GK.
    J Gastroenterol Hepatol; 2010 May 27; 25(5):880-5. PubMed ID: 20074149
    [Abstract] [Full Text] [Related]

  • 17. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
    Dig Dis Sci; 2008 Mar 27; 53(3):830-5. PubMed ID: 17939047
    [Abstract] [Full Text] [Related]

  • 18. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.
    Eur J Gastroenterol Hepatol; 2002 Dec 27; 14(12):1363-8. PubMed ID: 12468959
    [Abstract] [Full Text] [Related]

  • 19. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
    Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P, Terlipressin Study Group.
    J Hepatol; 2011 Aug 27; 55(2):315-21. PubMed ID: 21167235
    [Abstract] [Full Text] [Related]

  • 20. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.
    Ann Hepatol; 2009 Aug 27; 8(3):207-11. PubMed ID: 19841499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.